scholarly journals Avoiding exploitation in multinational covid-19 vaccine trials

BMJ ◽  
2021 ◽  
pp. n541
Author(s):  
Alexander A Iyer ◽  
Joseph Millum ◽  
Christine Grady ◽  
David Wendler
Keyword(s):  
Vaccine Trials

Despite Setbacks, Ca Vaccine Trials Continue

2011 ◽  
Vol 44 (5) ◽  
pp. 32
Author(s):  
NEIL OSTERWEIL
Keyword(s):  
Vaccine Trials

HPV VACCINE AND CERVICAL CANCER

2011 ◽  
pp. 108-115
Author(s):  
Vu Quoc Huy Nguyen
Keyword(s):  
Cervical Cancer ◽  
Relative Risk ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Preventive Strategy ◽  
Protective Effects ◽  
Papilloma Virus ◽  
Vaccine Trials ◽  
Close Relationship ◽  
The Relationship

Persistent infection with high-risk Human Papilloma Virus (HPV) has been identified as the causal factor of cervical cancer, with relative risk up to 300-400 folds. This very close relationship leads to the preventive strategy of vaccination against HPV infections and HPV-related lesions. The article describes molecular and immunologic characteristics of HPV, currently available HPV vaccines and its protective effects; the relationship between HPV vaccination and cervical cancer screening, and an introduction to therapeutic HPV vaccine trials.

Seeking participation in bovine TB vaccine trials

2021 ◽  
Vol 188 (10) ◽  
pp. 395-396
Author(s):  
Lindsay Heasman
Keyword(s):  
Vaccine Trials

scholarly journals Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net

BMJ ◽  
2014 ◽  
Vol 349 (dec10 5) ◽  
pp. g7518-g7518 ◽  
Author(s):  
S. E. Bellan ◽  
J. R. C. Pulliam ◽  
J. Dushoff ◽  
L. A. Meyers
Keyword(s):  
Virus Vaccine ◽  
Ebola Virus ◽  
Safety Net ◽  
Vaccine Trials ◽  
Therapeutic Safety

scholarly journals Exploration and Ethical Analysis of Open-Label Pediatric Vaccine Trials in a Pandemic

2021 ◽  
Author(s):  
Ian D. Wolfe ◽  
Angira Patel ◽  
Larry K. Kociolek ◽  
Asma Fazal ◽  
Ravi Jhaveri ◽  
...  
Keyword(s):  
Ethical Analysis ◽  
Open Label ◽  
Vaccine Trials

scholarly journals Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Shiho Chiba ◽  
Steven J. Frey ◽  
Peter J. Halfmann ◽  
Makoto Kuroda ◽  
Tadashi Maemura ◽  
...  
Keyword(s):  
Coat Protein ◽  
Infectious Virus ◽  
Neutralizing Antibody ◽  
Vaccine Platform ◽  
Death Rates ◽  
Widespread Distribution ◽  
Syrian Hamsters ◽  
Vaccine Trials ◽  
Multiple Copies ◽  
Antibody Titers

AbstractThe COVID-19 pandemic continues to wreak havoc as worldwide SARS-CoV-2 infection, hospitalization, and death rates climb unabated. Effective vaccines remain the most promising approach to counter SARS-CoV-2. Yet, while promising results are emerging from COVID-19 vaccine trials, the need for multiple doses and the challenges associated with the widespread distribution and administration of vaccines remain concerns. Here, we engineered the coat protein of the MS2 bacteriophage and generated nanoparticles displaying multiple copies of the SARS-CoV-2 spike (S) protein. The use of these nanoparticles as vaccines generated high neutralizing antibody titers and protected Syrian hamsters from a challenge with SARS-CoV-2 after a single immunization with no infectious virus detected in the lungs. This nanoparticle-based vaccine platform thus provides protection after a single immunization and may be broadly applicable for protecting against SARS-CoV-2 and future pathogens with pandemic potential.

scholarly journals Sex-disaggregated data in COVID-19 vaccine trials

The Lancet ◽  
2021 ◽  
Vol 397 (10278) ◽  
pp. 966-967
Author(s):  
Lavanya Vijayasingham ◽  
Evelyne Bischof ◽  
Jeannette Wolfe
Keyword(s):  
Vaccine Trials ◽  
Disaggregated Data
Sign in / Sign up

Export Citation Format

Share Document